Lantheus (NASDAQ:LNTH) Upgraded to “Strong-Buy” at Wall Street Zen

Lantheus (NASDAQ:LNTH) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a report issued on Saturday.

A number of other brokerages also recently commented on LNTH. William Blair raised Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday, February 26th. Truist Financial raised their target price on shares of Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a report on Friday, February 27th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Tuesday, February 24th. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Finally, Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $82.17.

Lantheus Trading Down 4.9%

Shares of LNTH stock opened at $72.56 on Friday. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. Lantheus has a twelve month low of $47.25 and a twelve month high of $111.29. The company’s 50-day moving average price is $69.11 and its 200-day moving average price is $60.90. The stock has a market cap of $4.69 billion, a price-to-earnings ratio of 21.53 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The firm had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. During the same period last year, the business earned $1.59 earnings per share. Lantheus’s revenue was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities analysts predict that Lantheus will post 6.01 earnings per share for the current year.

Hedge Funds Weigh In On Lantheus

A number of institutional investors have recently added to or reduced their stakes in LNTH. M&T Bank Corp acquired a new position in shares of Lantheus in the 4th quarter valued at approximately $370,950,000. Farallon Capital Management LLC grew its position in shares of Lantheus by 56.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after buying an additional 1,950,252 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Lantheus during the third quarter worth approximately $65,654,000. Norges Bank bought a new stake in shares of Lantheus in the fourth quarter worth $76,197,000. Finally, Polaris Capital Management LLC bought a new stake in shares of Lantheus in the third quarter worth $32,687,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.